Wealthfront Advisers LLC Purchases Shares of 1,043,153 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Wealthfront Advisers LLC purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,043,153 shares of the medical research company’s stock, valued at approximately $342,686,000. Wealthfront Advisers LLC owned approximately 3.73% of Bio-Rad Laboratories as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BIO. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bio-Rad Laboratories by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after buying an additional 4,260 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Bio-Rad Laboratories by 3.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after buying an additional 9,584 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $83,681,000. Mawer Investment Management Ltd. raised its holdings in shares of Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after buying an additional 84,237 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Bio-Rad Laboratories by 4.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock valued at $63,030,000 after buying an additional 7,552 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Price Performance

BIO opened at $249.43 on Tuesday. The firm has a market cap of $6.99 billion, a price-to-earnings ratio of -3.84 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a 1 year low of $244.19 and a 1 year high of $387.99. The stock’s 50 day simple moving average is $318.18 and its 200 day simple moving average is $329.93. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.